Synmosa Biopharma (ROCO:4114) ROCE % : 5.31% (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synmosa Biopharma's annualized ROCE % for the quarter that ended in Dec. 2024 was 5.31%.

Synmosa Biopharma ROCE % Historical Data

The historical data trend for Synmosa Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma ROCE % Chart

Synmosa Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

7.17

2.39

9.07

7.23

Synmosa Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															7.36	8.38	8.61	6.96	5.31

Synmosa Biopharma ROCE % Calculation

Synmosa Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	717.165	/	( ( (11728.587 - 2118.421)	+	(12304.141 - 2074.588) )	/ 2 )
	=	717.165	/	( (9610.166	+	10229.553)	/ 2 )
	=	717.165	/	9919.8595
	=	7.23 %

Synmosa Biopharma's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	540.508	/	( ( (12179.307 - 2061.66)	+	(12304.141 - 2074.588) )	/ 2 )
	=	540.508	/	( ( 10117.647	+	10229.553 )	/ 2 )
	=	540.508	/	10173.6
	=	5.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Synmosa Biopharma (ROCO:4114) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synmosa Biopharma ROCE % Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines